Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for chronic diseases with unmet medical need. The company utilizes a structure-based drug discovery platform and computational chemistry expertise to target G-protein coupled receptors (GPCRs). Its primary focus is the metabolic franchise, specifically obesity and related conditions such as type 2 diabetes, heart failure, and metabolic dysfunction-associated steatotic liver disease. Key product candidates include aleniglipron (GSBR-1290), an oral selective GLP-1 receptor agonist in Phase 3 clinical trials, and amylin receptor agonists ACCG-2671 and ACCG-3535. The company develops small molecule alternatives to injectable biologics and peptide therapies, leveraging the manufacturing scalability of small molecules. Structure Therapeutics partners with Schrödinger for computational chemistry capabilities and targets global markets for chronic metabolic and cardiopulmonary disorders.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage structuretx.com
Sector Healthcare IR page ir.structuretx.com
Tags
oral small molecules, obesity, glp-1 receptor agonists, amylin receptor agonists, gpcr biology, structure-based drug discovery, computational chemistry, type 2 diabetes, metabolic diseases, cardiovascular diseases, aleniglipron, GSBR-1290, ACCG-2671, ACCG-3535, Schrödinger
Press page —

Metrics

Valuation  
Market cap $ 6.695B
Market cap (USD) $ 6.695B
P/E -24.05
PEG —
P/BV 5.48
P/S —
P/OCF -24.70
P/FCF -24.14
Dividend yield —
Turnover / mcap —
Returns  
ROE -11.9%
ROI -19.6%
ROIC -18.4%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 32
Quality score -69.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Assets 1.584B 903.33M 482.017M 97.845M 111.155M
Net profit -141.202M -122.526M -89.62M -51.321M -40.008M
Free cash flow -225.813M -117.926M -81.655M -46.275M -33.366M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 69.55 27.12 40.76 — —
Price performance 12m 1.56 -0.33 — — —

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 260,000 5.45M 3.86M 6.49M
Cash and deposits (USD) 105M 26.1M 130M 170M 800M
Right-of-use assets (USD) — 262,000 5.14M 3.54M 6.25M
Cash flow detail
Operating cash flow (USD) — -46.1M -79.5M -117M -222M
Purchases of property, plant and equipment (USD) — -155,000 -2.17M -1.29M -3.61M
Change in payables (cash effect) (USD) — 2.15M -860,000 3.31M 4.77M
Income taxes paid (cash effect) (USD) — — -12,000 -370,000 -634,000
Share-based compensation (USD) — 2.51M 8.19M 18.8M 29M
Free cash flow (OCF - PPE - intangibles) (USD) — -46.3M -81.7M -118M -226M
Income detail
Research and development expense (USD) — 36.2M 70.1M 109M 225M
Total comprehensive income (USD) — -51.4M -89M -122M -141M
Comprehensive income to owners (USD) — -51.4M -89M -122M -141M
Reported May 11, 2023 Mar 8, 2024 Feb 26, 2026 Feb 26, 2026 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

and Recent Highlights

Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of

aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling;

topline data expected in 2H 2028

Additional aleniglipron data expected in Q4 2026

from supplementary body composition, type 2 diabetes and SWITCH studies

Reported Phase 1 SAD data for ACCG-2671 (oral small molecule amylin receptor agonist),

demonstrating a ~6-day half-life and no serious adverse events;

MAD clinical trial dosing underway, with topline data expected in 1H 2027

Cash, cash equivalents and short-term investments of $1.2 billion as of September 30, 2026

expected to fund projected operations and key clinical milestones through 2028

SAN FRANCISCO, November 9, 2026 (GLOBE NEWSWIRE) – Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30, 2026, and provided a business update across its oral small molecule obesity portfolio.

October 19, 2026

PDF Version

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026 in National Harbor, MD.

Title: Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extension Date/Time: November 15, 2026, 2:30 p.m. – 3:30 p.m. ET Location: Exhibit Hall BCD

Title: Dose-Ranging Effects of Aleniglipron, an Oral Small-Molecule GLP-1RA for Obesity: The ACCESS Trials Date/Time: November 15, 2026, 2:30 p.m. – 3:30 p.m. ET Location: Exhibit Hall BCD

About Aleniglipron Aleniglipron (GSBR-1290) is an investigational, once-daily, orally available small molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor, a clinically validated target for the treatment of obesity and type 2 diabetes mellitus. Discovered through Structure Therapeutics’ structure-based drug discovery platform, aleniglipron was designed as a biased G protein-coupled receptor agonist that selectively activates the G-protein signaling pathway.

About Structure Therapeutics Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.

Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC 212-915-2577 [email protected]

Jen Robinson Structure Therapeutics Inc. [email protected]

Media: Dan Budwick 1AB [email protected]

Print Page

Email Alerts

RSS Feeds

Search

Scroll to top

Structure Therapeutics Reports Positive Clinical Data Across Bull 5 Bear 0 Clinical/regulatory

Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life,

no serious adverse events, and evidence of target engagement including

up to 3.3% body weight loss in Phase 1/2a SAD clinical trial

First participants dosed with ACCG-2671 in the 12-week MAD portion

of the Phase 1/2a clinical trial; topline data expected in 1H 2027

Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated

up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau,

and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug

discontinuation rates due to adverse events in the ACCESS OLE clinical trial

ACCOMPLISH-1 and ACCOMPLISH-2 registrational Phase 3 clinical trials

for aleniglipron enrollment ongoing; topline data expected in 2H 2028

Company to host conference call today at 8:30 a.m. ET

SAN FRANCISCO, September 8, 2026 – Structure Therapeutics Inc.

Prompts

Structure Therapeutics Inc. (ticker GPCR), listed in United States.

Company History

Date Change Detail
Mar 14, 2022 Renamed ShouTi Inc. → STRUCTURE THERAPEUTICS INC.

ETFs Holding Structure Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
LRNZ 4.30% 33,600 $ 1.803M Jun 30, 2026
OZEM 2.77% 85,120 $ 1.547M Nov 17, 2026
MID 0.60% 13,657 $ 626.993K Aug 31, 2026
FDG 0.56% 51,502 $ 2.364M Aug 31, 2026
GDOC 0.43% 1,838 $ 84.383K Aug 31, 2026
FMED 0.41% 4,628 $ 212.471K Aug 31, 2026
FFSM 0.15% 47,095 $ 2.262M Jul 31, 2026
APIE 0.03% 7,237 $ 332.251K Aug 31, 2026
MSSM 0.01% 2,258 $ 103.665K Aug 31, 2026